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ABSTRACT
Cancer has been treated with radiopharmaceuticals for 80 years. A recent National Cancer Research Institute report from
the Clinical and Translational Radiotherapy ResearchWorking Group reviews the current status of molecular radiotherapy
and has highlighted the barriers to and opportunities for increased research activities. The report recommends a number
of actions to promote this field, which in the dawning age of personalized medicine and theragnostics is of increasing
importance, particularly with the clinical introduction of a range of new commercial radiotherapeutics at costs in line with
those seen for conventional chemotherapeutics. These recommendations recognize the importance of a multidisciplinary
approach to the development of molecular radiotherapy and the particular need for investment in radiopharmacies and
personalized dosimetry. There are many areas to be investigated including adaptive treatment planning, the use of
radiosensitizers and translational radiation biology. Progress in these areas will result in significant patient benefit and
more cost-effective use of increasingly expensive therapeutic radiopharmaceuticals. A concerted effort from the
community, from funding bodies and from health service providers is now needed to address the scientific and logistical
changes necessary to realize the potential offered by this currently underused treatment modality.
INTRODUCTION
Radioiodine therapy was conceived in 1936 following
a meeting between the clinician Saul Hertz and the phys-
icist Karl Compton.1 Initial treatments were performed
with radiation measurements and dosimetric analysis. On
the 80th anniversary of this auspicious meeting, a National
Cancer Research Institute (NCRI) report, produced by the
Clinical and Translational Radiotherapy Research Working
Group (CTRad), has highlighted the dramatic changes that
are under way, the huge challenges faced and the great
potential for development of molecular radiotherapy
(MRT).2 In 2003, a similar report for external beam ra-
diotherapy (EBRT) highlighted the need for investment in
research that led to the formation of the CTRad.3
CTRad was established in 2009 by the NCRI with a clear
mission to promote clinical and translational research in
radiation oncology. Members include clinical oncologists
and clinicians from other disciplines, radiographers,
physicists and other scientists. CTRad has four work
streams covering the science base, early and late phase
clinical trials, and physics and new technologies. CTRad
activities include support for the development of clinical
trials; advice on radiotherapy quality assurance (QA) in
clinical trials; and partnership with the pharmaceutical
industry to investigate drug–radiation interactions. The
achievements of CTRad in its ﬁrst quinquennium, and its
vision for the future, are well documented.4
The report entitled “CTRad : Identifying opportunities to
promote progress in molecular radiotherapy research in
the UK” was the result of multiprofessional input from
a number of key individuals and professional bodies in-
terested in molecular oncology research. The aim of the
report included identiﬁcation of the strengths and weak-
nesses of MRT research in the UK and identiﬁcation of the
barriers to research. The report recognizes the importance
of MRT as a cancer therapy and acknowledges that there
needs to be a signiﬁcant increase in clinical and trans-
lational research activity in the ﬁeld.
The report was compiled using data from a CTRad MRT
questionnaire, sent to 58 National Health Service nuclear
medicine departments, as well as interviews with UK MRT
professionals.
There are 10 recommendations in total, the key recom-
mendations being:
– the establishment of a forum through which the MRT
community can better engage with research funders and
potential collaborators
– funding to increase the number of appropriately trained MRT
professionals with protected research time
– increased investment in radiopharmacies
– routine dosimetry-based treatment planning for MRT
– the establishment of a national QA group to deliver full QA in
MRT trials.
The report introduces remarkable potential for development, in
many cases along similar lines as are seen for EBRT, which will
result in improved patient beneﬁt. Avenues for exploration in-
clude the following.
Radiosensitizers and concomitant administration
of chemotherapeutics
The targeting agent is simply a vector to deliver the radionuclide
to the tumour cells. Cytotoxicity results from the emitted radi-
ation causing single- and double-strand breaks in the nuclear
DNA. As cells have some intrinsic ability to repair potentially
lethal damage, concomitant administration of drugs which may
interfere with this may act as radiosensitizers.5 There is labo-
ratory evidence of synergistic interactions between MRT and
both topoisomerase 1 inhibitors (for example topotecan)6 and
poly(ADP-ribose) polymerase inhibitors (for example ola-
parib).7 There is as yet no clinical evidence that combinations of
DNA repairing inhibitors and MRT are truly an improvement
over MRT alone, but combinations are feasible to deliver.8
Clinical and pre-clinical research is essential to evaluate the true
beneﬁt of these combinations.
Translational radiation biology
The recent developments in MRT have highlighted the need for
high-quality radiation biology research to maximize its future
translational potential. For radionuclide exposures, the absorbed
dose deposition and subsequent biological response is constrained
by two key physical parameters—the decay rate of the isotope
(and hence the absorbed dose rate) and the type of radiation
decay, i.e. the radiation quality (or linear energy transfer). Un-
derstanding the relationship of this to individual patient treat-
ments from a dosimetric perspective needs both pre-clinical and
clinical research. From a biological perspective, there is now rapid
progression from an understanding of a direct DNA damage
response-driven mechanism to more complex signalling-driven
mechanisms where the triggering of systemic responses, including
activation of immune responses, has the potential to deliver sig-
niﬁcant patient beneﬁts in the metastatic setting.9,10 To translate
studies through to clinical application, understanding is needed of
the underpinning mechanisms of MRT exposures. This requires
fundamental radiation biology research in relevant pre-clinical
models which mimic the clinical situation, including in-
dividualized tumour responses. In addition, trained research
personnel with the expertise to deliver high-quality pre-clinical
studies in advanced tumour models are urgently required.
Adaptive treatment planning
It has been demonstrated extensively that while the range of
absorbed doses delivered to different patients varies widely,
sequential treatments for several therapy procedures, particularly
those given within 4–6 weeks, result in similar biokinetics.11,12
This introduces the strong potential to perform adaptive treat-
ment planning, whereby activities are calculated to deliver
a prescribed absorbed dose. Clinical trials are urgently needed to
determine whether such an approach is feasible.
Combined molecular radiotherapy and external
beam radiotherapy
For many diseases in which MRT may have a role, there is also
a place for EBRT. An example is neuroblastoma, where mIBG
therapy for refractory disease may be followed by EBRT to the
primary tumour site, and possibly also residual distant meta-
static sites. For optimal tumour kill, and to avoid excess late
effects on normal tissues, it is essential to know not just the
physical but also the biological effect of both modalities
individually and combined.13 This important area is poorly
understood and should be a priority for future clinical and pre-
clinical research programmes.
DISCUSSION
The lack of development in MRT relative to the progression
seen in EBRT is understandable and is not limited to the UK. A
small number of patients are treated with this modality, usually
with rare cancers and often only with palliative intent. An
exception is the treatment of thyroid cancer with radioiodine,
which in patients at low risk has proven so successful that
treatments have remained essentially unchanged in the 80 years
since it was ﬁrst used. This has helped perpetuate the myth of
the “magic bullet”.
It is no exaggeration to say that MRT is now entering a new era
that will cause signiﬁcant changes at all levels. A number of new
innovative radiotherapeutics are entering the clinic at costs
similar to those for conventional chemotherapeutics, necessi-
tating health economic evaluation at a national level. Revision of
the risks to patients from planned and unplanned treatments is
of increasing importance in Europe, with the introduction of
a directive due to be enacted in February 2018 concerned with
basic safety standards.14
MRT is increasingly regarded as a form of radiotherapy rather
than chemotherapy, whereby activities should be administered
according to personalized treatment planning, based on the
absorbed doses delivered to target volumes and to normal tis-
sues. Such a sea change offers unprecedented opportunities for
a multidisciplinary approach to personalized treatment, but will
require a major revision of infrastructure, resourcing and
management that must involve all related disciplines and
organizations.
The recent NCRI/CTRad report clearly articulates a range of
research activity and barriers for MRT in the UK and lays out
strategic priorities that will be of signiﬁcant beneﬁt to the re-
search community.
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